Trials / No Longer Available
No Longer AvailableNCT04617535
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.
Detailed description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN10933+REGN10987 combination therapy | Administered intravenously (IV) single dose |
Timeline
- First posted
- 2020-11-05
- Last updated
- 2023-10-03
Source: ClinicalTrials.gov record NCT04617535. Inclusion in this directory is not an endorsement.